Saturday 7 November 2026 Export JAGX’s income statement to Excel — free account

Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024.

Revenue: −58.9%
EPS: +95.6%
Free cash flow: +13.8%
Total debt: −83.9%

Quarter to June 2026, against a year earlier

0.40 0.01 −2.44%

Follow JAGX

Alert me

Market cap: $950.0K
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 3/9
Altman Z: −18.88
Beneish M: −6.24
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 0.95

Revenue ttm 27.82

Net income ttm (37.50)

Free cash flow ttm (6.68)

Net debt Q (4.86)

Valuation

P/E 0.00

Forward P/E (0.67)

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 0.69

Debt / equity Q 0.35

Interest coverage Q (47.19)

Growth

Revenue growth Q −58.88%

Operating income growth Q +5.12%

EPS, this year +99.51%

EPS, next year A −125.00%

Revenue, next year A +77.74%

EPS, past 5 yrs —

EPS, next 5 yrs A +87.27%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.08%

10-year low 10-year high

P/B against its own 10 years 0.05%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	8	8	7
Receivables	2	2	2	0
Inventory	9	10	9	7
Other	—	—	—	—
	28	32	20	18

	2023	2024	2025	Q'26
Payables	5	5	9	5
ST’ Debt	—	—	—	—
Other	—	—	—	2
	14	20	41	25

Compound Annual Growth %

	10y	5y	3y
Sales	46.18%	4.17%	(1.26%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY19 Estimate −44,523,896.00 Actual −345,505,440.00

−47,233,536,762.80 −33,897,511,387.40 −20,561,486,012.00 −7,225,460,636.60 6,110,564,738.80

Q2 FY17 Beat +18,672,023,552.00

Q1 FY19 Beat +124,542,208.00

Q2 FY19 Miss −619,772,672.00

Q3 FY19 Miss −300,981,544.00

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY17	−41,078,448,128.00	−22,406,424,576.00	Beat by 18,672,023,552.00
Q1 FY19	−2,366,305,024.00	−2,241,762,816.00	Beat by 124,542,208.00
Q2 FY19	−999,116,288.00	−1,618,888,960.00	Miss by 619,772,672.00
Q3 FY19	−44,523,896.00	−345,505,440.00	Miss by 300,981,544.00

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(203.90)	(235.38)	—	—	—
’25	(8.75k)	(5.38k)	(3.29k)	(1.97k)	(12.04k)
’24	(47.37k)	(53.02k)	(13.76k)	(8.63k)	(68.51k)
’23	(2.43)	(331.58k)	(300.00k)	(576.80k)	(1.41m)
’22	(23.32)	(8.79)	(8.89)	4.10	(36.90)
’21	(0.28)	(0.31)	(0.27)	(1.23m)	(88.23)
’20	(0.52)	(0.39)	(0.59)	(1.13)	(3.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	20	1	—	—	—
’25	2	3	3	3	12
’24	2	3	3	4	12
’23	2	3	3	2	10
’22	3	3	3	3	12
’21	1	0	1	2	4
’20	1	3	3	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(5)	—	—	—
’25	(7)	(6)	(5)	(5)	(24)
’24	(7)	(8)	(6)	(8)	(29)
’23	(10)	(9)	(7)	(7)	(33)
’22	(8)	(10)	(9)	(6)	(33)
’21	(7)	(10)	(9)	(9)	(35)
’20	(4)	(4)	(3)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(5)	—	—	—
’25	(7)	(6)	(5)	(6)	(24)
’24	(7)	(8)	(6)	(8)	(30)
’23	(10)	(9)	(7)	(7)	(33)
’22	(8)	(13)	(9)	(7)	(35)
’21	(7)	(10)	(9)	(9)	(35)
’20	(4)	(4)	(3)	(4)	(15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	4	4	6	9	4	12	10	12	12	28		+63.0%	20	14	—	+10.7%
	Gross margin, %	63.32	79.81	37.37	33.92	65.05	46.18	83.11	79.13	83.27	67.21	82.31		+3.9 pt	Powerpack Jaguar Animal Health, Inc.’s next three years, line by line Analysts expect revenue to grow 10.7% a year to 2028 — slower than the 63.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(15)	(35)	(32)	(39)	(34)	(53)	(48)	(42)	(39)	(54)	(37)		+15.5%
	EBT margin, %	(10,412.58)	(805.97)	(727.93)	(667.17)	(360.25)	(1,213.38)	(404.78)	(429.27)	(335.79)	(469.09)	(132.73)		+9,943.5 pt
	Net income	(15)	(22)	(32)	(39)	(34)	(53)	(49)	(42)	(39)	(54)	(38)		+15.6%
Per share, $
Per share, $	Revenue	0.01	1.51	21.06	1.16	0.73	7.27	9.12	332,308.59	19,481.67	2,616.14	515.09		+288.8%
	Earnings	(1.35)	(7.59)	(153.27)	(9.01)	(3.00)	(88.23)	(36.90)	(1,406,039.25)	(68,509.46)	(12,041.18)	(5,703.97)		+174.8%
	Cash flow	(1.32)	(3.39)	(108.40)	(4.12)	(1.19)	(58.65)	(25.24)	(1,131,708.05)	(48,973.33)	(5,383.18)	(123.80)		+151.9%
	Capex	(0.01)	0.00	(0.03)	0.00	0.00	(0.01)	(1.28)	0.00	(385.00)	(9.32)	0.00		+115.0%
	Free cash flow	(1.33)	(3.39)	(108.43)	(4.12)	(1.19)	(58.66)	(26.52)	(1,131,708.05)	(49,358.33)	(5,392.50)	(123.80)		+151.8%
	Book value	(0.22)	5.96	68.59	4.14	1.34	19.88	(1.03)	166,716.03	10,823.33	(4,247.27)	91.13		+198.7%
	Shares, m	11	3	0	5	13	1	1	0	0	0	0		(58.1%)
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	9,661,624,906,836.67	18,282,754,417.67	134,870,293.78	122,027,886.88	143,369,721.88	8,447,885.81	570,133.93	0.00	0.94	0.36	0.00		968,031,694,717.8
	P/B	0.00	4,619,252,667.34	110,645,202.84	78,642,009.45	78,219,093.12	3,089,646.92	0.00	0.00	1.70	0.00	0.00		488,984,862.1
	EV/Sales	9,661,624,906,852.75	18,282,754,420.39	134,870,295.98	122,027,886.56	143,369,722.51	8,447,888.02	570,135.09	2.68	2.41	1.13	(0.12)		968,031,694,720.8
	EV/FCF	(94,167,884,082.39)	(8,030,226,334.99)	(26,195,467.41)	(34,436,622.60)	(88,029,103.42)	(1,047,049.25)	(189,543.01)	(0.72)	(0.90)	(0.53)	0.44		(10,234,800,820.5)
Cash, $m
Cash, $m	Operating cash flow	(14)	(10)	(23)	(20)	(15)	(35)	(33)	(33)	(29)	(24)	(7)		+5.7%
	Capex	0	—	0	—	0	0	(2)	0	0	0	0		(9.8%)
	Free cash flow	(15)	(10)	(23)	(20)	(15)	(35)	(35)	(33)	(30)	(24)	(7)		+5.6%
Balance, $m
Balance, $m	Working capital	(2)	(12)	(19)	(6)	5	13	(8)	14	12	(20)	(8)		+32.3%
	Net debt	2	12	(3)	(3)	4	8	12	25	16	7	(5)		+13.7%
	Shareholders’ equity	(2)	17	14	21	17	12	(1)	5	6	(19)	5		+25.3%
Returns, %
Returns, %	ROA	(184.54)	(93.10)	(75.93)	(115.49)	(97.53)	(109.45)	(94.23)	(84.10)	(73.89)	(116.79)	(127.14)		+67.8 pt
	ROIC	0.00	(73.57)	(163.06)	(105.59)	(77.34)	(128.34)	(196.99)	(72.85)	(87.61)	0.00	(28,393.64)		0.0 pt
	ROE	(1,515.12)	(296.74)	(283.92)	(623.62)	(295.44)	(362.04)	(904.14)	(2,332.67)	(675.83)	729.95	(1,125.38)		+2,245.1 pt
People
People	Employees	23	36	40	29	34	52	60	49	49	49	—		+8.8%
	Revenue/emp, $m	0.01	0.12	0.11	0.20	0.28	0.08	0.20	0.20	0.24	0.23	—		+49.9%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$1.3M	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
ARTL Artelo Biosciences, Inc.	$1.2M	— (loss-making)	—	—	n/m	−879.18% (below 0%: shrinking)	0.00%	0.00%	Compare
MTNB Matinas Biopharma Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	0.00%	n/m	+9.15% (above 0%: growing)	0.00%	0.00%	Compare
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	—	0.00%	Compare
VBIO Valion Bio, Inc.	$1.1M	— (loss-making)	— (loss-making)	+15.87% (above 0%: growing)	n/m	−189.01% (below 0%: shrinking)	(99.32%)	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
JAGX Jaguar Animal Health, Inc.	$950.0K	— (loss-making)	— (loss-making)	−58.88% (below 0%: shrinking)	n/m	+13.83% (above 0%: growing)	15.84%	(620.16%)
SPRC SciSparc Ltd.	$880.0K	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
LNAI Lunai Bioworks Inc.	$830.0K	— (loss-making)	—	—	n/m	−1.65% (below 0%: shrinking)	100.00%	(6,877.49%)	Compare
Median of peers	$1.1M	—	—	0.00%	—	+4.49%	0.00%	0.00%

All 621 Biotechnology stocks →

Jaguar Animal Health, Inc. (JAGX) Latest News

21 Oct

Impact 4 · 9:00 AM · ACCESS Newswire

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

14 Oct

Impact 4 · 9:00 AM · ACCESS Newswire

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Impact 3 · 4:15 PM · ACCESS Newswire

Jaguar Health Provides Update Regarding Special Stock Dividend

13 Oct

Impact 4 · 9:00 AM · ACCESS Newswire

Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

6 Oct

Impact 4 · 10:53 AM · InvestorsHub

Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances

Impact 4 · 9:00 AM · ACCESS Newswire

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

2 Oct

Impact 4 · 8:35 PM · ACCESS Newswire

Jaguar Health Announces a Special Stock Dividend

29 Sep

Impact 4 · 7:46 AM · InvestorsHub

Napo Pharmaceuticals Crofelemer Study Accepted for Presentation at ACG 2026

Impact 3 · 4:30 AM

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

25 Sep

Impact 4 · 10:49 AM · 24/7 Wall St.

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

23 Sep

Impact 4 · 4:05 AM · Stocktwits

JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: What’s Driving The Surge?

22 Sep

Impact 3 · 9:05 AM · ACCESS Newswire

Jaguar Health Receives Fee Waivers from FDA

10 Sep

Impact 3 · 9:00 AM

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

20 Aug

Impact 4 · 1:02 AM transcript

Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...

28 Jul

Impact 3 · 9:00 AM

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

30 Jun

Impact 3 · 9:00 AM

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

23 Jun

Impact 4 · 9:00 AM · ACCESS Newswire

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

22 Jun

Impact 4 · 9:00 AM · ACCESS Newswire

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

28 May

Impact 3 · 10:00 AM · ACCESS Newswire

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

26 May

Impact 4 · 5:00 PM · GuruFocus.com transcript

Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

21 May

Impact 4 · 5:10 PM · The Motley Fool transcript

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

20 May

Impact 4 · 12:41 PM · The Motley Fool transcript

Jaguar (JAGX) Q4 2025 Earnings Transcript

Impact 3 · 4:40 PM · ACCESS Newswire

Jaguar Health Reports First Quarter 2026 Financials

19 May

Impact 4 · 9:00 AM · ACCESS Newswire

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

8 May

Impact 4 · 9:00 AM · ACCESS Newswire

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

6 May

Impact 4 · 9:00 AM

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

4 May

Impact 4 · 8:30 AM · ACCESS Newswire

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

29 Apr

Impact 4 · 8:30 AM · ACCESS Newswire

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

27 Apr

Impact 4 · 9:00 AM

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

24 Apr

Impact 4 · 8:30 AM · ACCESS Newswire

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Jaguar Animal Health, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Jaguar Animal Health, Inc. (JAGX) Latest News

21 Oct

14 Oct

13 Oct

6 Oct

2 Oct

29 Sep

25 Sep

23 Sep

22 Sep

10 Sep

20 Aug

28 Jul

30 Jun

23 Jun

22 Jun

28 May

26 May

21 May

20 May

19 May

8 May

6 May

4 May

29 Apr

27 Apr

24 Apr

Stockrow Weekly